Good
Mostly Aligned
Patient Risk:
Low
Summary
The only provided AI claim is supported by the FDA-approved Indications and Usage for Kerendia in adults with CKD associated with T2DM. No other dosing, safety, contraindication, or interaction claims were evaluated.
Category Scores
Accurate Statements
Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD associated with T2DM.
Section 1 (INDICATIONS AND USAGE): “Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM).”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No safety-related claims, dosing instructions, contraindications, or monitoring statements were made beyond the on-label indication.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
If additional label content is relevant (e.g., the heart failure indication or dosing/monitoring details), include and evaluate those sections as well.